Download Windows 8.1

Get your hands on Windows 8.1

Windows 8.1 brings you exciting new ways to use your PC. It's fast, fluid, intuitive, and designed to let you do what you want, the way you want.

http://windows.microsoft.com/en-in/windows/buy?ocid=GA8_O_WOL_DIS_ShopHP_FPP_Light

You'll love Windows 8.1

Windows 8.1 gives you the familiar desktop with its taskbar and Start button, plus a beautiful new Start screen that you can customize with your favorite apps, people, and sites so that everything you love is just a tap or click away.

You also get built-in cloud storage for anytime, anywhere access to your photos and files with OneDrive, beautiful full-screen browsing with Internet Explorer 11, plus an exclusive collection of built-in apps like Photos and Mail, with many more apps available from the Windows Store. And that’s only the beginning.

System requirements

To install the free update to Windows 8.1 or Windows 8.1 Pro through the Windows Store, your PC must be running Windows 8 or Windows 8 Pro.
For more information, read the full terms and conditions.

1 GHz processor or faster with support for PAE, NX, and SSE2
2 GB RAM / 20 GB available hard disk space
1024 × 768 screen resolution
DirectX 9 graphics processor with WDDM driver
To use touch, you need a PC that supports multitouch

Internet access (fees may apply)
Microsoft account required for some features
Watching DVDs requires separate playback software
Windows Media Center license sold separately
See the full system requirements

Comments

The first drug for a common, deadly liver disease is here – and more are coming

VIEW IN BROWSER | SUBSCRIBE TUE, MAR 19, 2024 EDITOR'S NOTE Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good morning! Millions of Americans with a common and potentially life-threatening form of liver disease will soon have access to the first-ever treatment for the condition. In a landmark decision on Thursday, the Food and Drug Administration approved Madrigal Pharmaceuticals ' drug " Rezdiffra ," to be used along with diet and exercise. The company expects the medicine to be available next month with a hefty price tag of $47,400 per year before insurance and other rebates. So, why is this approval so important? First of all, people suffering from the disease badly need a treatment. Rezdiffra is specifically approved to treat patients with nonalcoholic steatoh

J&J, Merck and Bristol Myers Squibb are in the hot seat

VIEW IN BROWSER | SUBSCRIBE TUE, JAN 30, 2024 EDITOR'S NOTE Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! This is Annika Kim Constantino, and I cover the biotech and pharmaceutical industry for CNBC.com . Three names in the industry – Johnson & Johnson, Merck and Bristol Myers Squibb – face a pivotal few weeks ahead. CEOs from those companies are slated to testify at a Senate hearing on high prescription drug prices in the U.S. on Feb. 8 at 10 a.m. ET, Sen. Bernie Sanders announced Friday. It took subpoena threats from the senator, but J&J CEO Joaquin Duato and Merck CEO Robert Davis have agreed to testify after both executives declined earlier requests to appear at the Senate HELP committee's hearing. They join Bristol Myers Squibb CEO Chris Boerner, who agr

How competitive can Roche be in the weight loss drug market?

VIEW IN BROWSER | SUBSCRIBE TUE, SEP 17, 2024 EDITOR'S NOTE Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! Roche is one of several drugmakers hoping to join the booming weight loss drug market, which Novo Nordisk and Eli Lilly are currently dominating. But can the Swiss company develop drugs that can compete with that duopoly? The answer isn't clear yet. We need to see more data from longer and larger clinical trials, which will likely take years for Roche to conduct. But the company last week presented more early-stage data more early-stage data on its experimental obesity injection and pill, which some analysts said raised concerns about how competitive those products can be if they enter the space. Some analysts said the new results showed that both drugs – which Roche acquired through its nearly $3 billion acquisition of Carmot Therapeutics in December – caused a higher rate of side

DBTECH

Search This Blog